Lumos Pharma (NASDAQ:LUMO) Trading Down 0.7% – Should You Sell?

Lumos Pharma, Inc. (NASDAQ:LUMO) dropped 0.7% during mid-day trading on Tuesday . The company traded as low as $4.35 and last traded at $4.35. Approximately 43,001 shares were traded during trading, a decline of 20% from the average daily volume of 53,532 shares. The stock had previously closed at $4.38.

Analyst Ratings Changes

LUMO has been the subject of a number of analyst reports. HC Wainwright restated a “neutral” rating and set a $4.25 price objective on shares of Lumos Pharma in a report on Friday, November 8th. EF Hutton Acquisition Co. I upgraded shares of Lumos Pharma to a “strong-buy” rating in a report on Tuesday, September 24th.

Lumos Pharma Stock Down 0.7 %

The company has a market cap of $37.63 million, a price-to-earnings ratio of -1.01 and a beta of 0.74. The company’s fifty day moving average price is $4.14 and its two-hundred day moving average price is $3.14.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lumos Pharma stock. Private Advisor Group LLC grew its stake in Lumos Pharma, Inc. (NASDAQ:LUMO) by 2,380.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 744,513 shares of the company’s stock after buying an additional 714,500 shares during the quarter. Private Advisor Group LLC owned 9.17% of Lumos Pharma worth $2,881,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 33.99% of the company’s stock.

Lumos Pharma Company Profile

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.